Last week’s deal-making news included US biotech Alumis signing a licensing agreement with Japan’s Kaken Pharma for its ...

US gene therapy company bluebird bio (Nasdaq: BLUE) has confirmed receipt of an unsolicited non-binding written proposal from ...

The interleukin-2 (IL-2) therapies market in the USA is poised for major growth, projected to reach $4 billion by 2034, ...

The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to ...

The European Medicines Agency’s (EMA’) human medicines committee (CHMP) has recommended two new medicines and three ...

German life sciences and pharma company Merck KGaA (MRK: DE) today revealed it has exercised its option with China’s Abbisko ...

US genomics firm Galatea Bio has raised $25 million in funding to expand its global biobank and accelerate the development of ...

Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility ...

US pharma major Merck & Co (NYSE: MRK) has shared the first results from a late-stage trial of a subcutaneous version of its ...

Singaporean biotech Shanton Pharma has reported positive top-line results from a Phase IIb clinical trial of its ...

Cardiovascular-focused Milestone Pharmaceuticals was trading more than 60% lower early in trading on Friday, with its share ...

Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...